1. Cerebrospinal Fluid Biomarkers in Familial Forms of Alzheimer's Disease and Frontotemporal Dementia
   Nina Rostgaard et al, 2015, Dementia and Geriatric Cognitive Disorders CrossRef
2. Mirror Image of the Amyloid-β Species in Cerebrospinal Fluid and Cerebral Amyloid in Alzheimer’s Disease
   Marcella Catania et al, 2015, Journal of Alzheimer's Disease CrossRef
3. The effects of different familial Alzheimer’s disease mutations on APP processing in vivo
   Steinunn Thordardottir et al, 2017, Alzheimer's Research & Therapy CrossRef
4. Biomedical Involvements of Low-Abundance Proteins
   Pier Giorgio Righetti et al, 2013, Low-Abundance Proteome Discovery CrossRef
5. Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease
   Marta Pera et al, 2013, Acta Neuropathologica CrossRef
6. Alzheimer's disease — Recent biomarker developments in relation to updated diagnostic criteria
   Kina Höglund et al, 2015, Clinica Chimica Acta CrossRef
7. Asymptomatic Carriers of Presenilin-1 E318G Variant Show no Cerebrospinal Fluid Biochemical Signs Suggestive of Alzheimer’s disease in a Family with Late-onset Dementia
   Vladimiro Artuso et al, 2018, Current Alzheimer Research CrossRef
8. Amyloid β Proteoforms Elucidated by Quantitative LC/MS in the 5xFAD Mouse Model of Alzheimer’s Disease
   Soumya Kandi et al, 2023, Journal of Proteome Research CrossRef
9. Specific Triazine Herbicides Induce Amyloid-β42 Production
   Erik Portelius et al, 2016, Journal of Alzheimer's Disease CrossRef
10. Systems Medicine as a Strategy to Deal with Alzheimer’s Disease
    Xiao Xue Zeng et al, 2023, Journal of Alzheimer's Disease CrossRef
11. Translational proteomics in Alzheimer's disease and related disorders
    Roberta Ghidoni et al, 2013, Clinical Biochemistry CrossRef
12. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry
    Piotr Lewczuk et al, 2018, The World Journal of Biological Psychiatry CrossRef
13. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ-secretase modulator, E2212, in healthy human subjects
    Yanke Yu et al, 2014, The Journal of Clinical Pharmacology CrossRef
14. Alzheimer's Disease Biomarker Analysis Using Targeted Mass Spectrometry
    Johan Gobom et al, 2024, Molecular & Cellular Proteomics CrossRef
15. Quantitative Proteomics in Development of Disease Protein Biomarkers
    Xudong Yao et al, 2013, Proteomic and Metabolomic Approaches to Biomarker Discovery CrossRef
16. Quantitative proteomics in development of disease protein biomarkers
    Lei Wang et al, 2020, Proteomic and Metabolomic Approaches to Biomarker Discovery CrossRef
17. Modeling the β-secretase cleavage site and humanizing amyloid-beta precursor protein in rat and mouse to study Alzheimer’s disease
    Lutgarde Serneels et al, 2020, Molecular Neurodegeneration CrossRef